Brief: Neuren Pharmaceuticals Says HY Net Loss Attributable A$7.1 Million
24/08/2022 02:33
Aug 24 (Reuters) - Neuren Pharmaceuticals NEU.AX :
* HY NET LOSS ATTRIBUTABLE A$7.1 MILLION VERSUS LOSS OF A$8
MILLION
Source text for Eikon: ID:nASX52wgx4
Further company coverage: NEU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neuren Pharmaceuticals
See all newsAustralia's Neuren set for weekly gain on FDA nod, drug forecast upgrade
Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union